Magnus Lindskog – Clinical and epidemiological studies to identify optimal treatment strategies for chemo-resistant cancers

In our research we study patients whose cancers are inherently resistant to chemotherapeutic drugs, focusing on kidney cancer, non-small cell lung cancer and malignant brain tumours (primary and metastatic). Notably, these diseases may respond to modern treatment strategies including immunotherapy, targeted agents and stereotactic radiotherapy. Aggressive surgery of primary tumours as well as oligo-metastases may also be beneficial. The challenge, however, is to select the patients most likely to benefit from such approaches.
 
Our aim is therefore to identify clinically relevant predictive factors as well as optimal treatment combinations or sequences. To this end we pursue innovative clinical trials, real world analyses, register studies and collaborative translational approaches. In an additional project, we study end-of-life care for cancer patients in Sweden, aiming to identify factors associated with quality of care and symptom relief.